Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 153Lung Neoplasms 73Pancreatic Neoplasms 44Neoplasms 27Neoplasm Metastasis 25Head and Neck Neoplasms 23Brain Neoplasms 21Breast Neoplasms 18Glioblastoma 15Adenocarcinoma of Lung 15Squamous Cell Carcinoma of Head and Neck 14Gliosarcoma 14Adenocarcinoma, Bronchiolo-Alveolar 11Colorectal Neoplasms 10Glioma 9Carcinoma, Squamous Cell 8Carcinoma, Hepatocellular 8Adenocarcinoma 7Rectal Neoplasms 6Prostatic Neoplasms 6Esophageal Neoplasms 6Central Nervous System Neoplasms 6Carcinoma, Renal Cell 6Astrocytoma 6Oligodendroglioma 5Liver Neoplasms 5Colonic Neoplasms 5Carcinoma 5Recurrence 4Ovarian Neoplasms 4

Interventions

apatinib 2Erlotinib Hydrochloride 2Carboplatin 2sintilimab 1durvalumab 1camrelizumab 1Vinorelbine 1Tyrosine Kinase Inhibitors 1Telescopes 1Radiotherapy 1Radiosurgery 1Pemetrexed 1Gemcitabine 1Gefitinib 1Etoposide 1Docetaxel 1Dasatinib 1Cisplatin 1Afatinib 14-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Respiratory Tract Diseases × Erlotinib Hydrochloride × Clear all
NCT03389256 2018-01-03

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Sichuan Cancer Hospital and Research Institute

Phase 2 Unknown
144 enrolled
Thoracic

Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT01024413 2017-03-01

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Chinese Society of Lung Cancer

Phase 3 Completed
256 enrolled
Thoracic

Lung Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡